Therapeutic proteins provide unique treatments for numerous human diseases and disorders including cancer, multiple sclerosis, hemophilia, rheumatoid arthritis, Crohn's disease and diabetes. Unfortunately, in significant fractions of patients receiving therapeutic protein products (up to 50% or higher), efficacy is lost due to immune response to the product. Immunogenicity may be stimulated by the presence of protein aggregates. In this project, we will use a hierarchical approach that uses advanced computer simulations combined with state-of-the art experiments to provide detailed, molecular-level information on the mechanisms by which protein aggregation occurs. Experiments will utilize synthetic proteins with designed chemical characteristics, model therapeutic proteins in murine models and commercial therapeutic proteins. Protein aggregates and pathways for their formation will be analyzed using a wide array of experimental techniques including single-molecule total internal reflectance fluorescence-Forster resonant energy transfer, small angle neutron scattering, small angle x-ray scattering micro-flow imaging, surface micro-rheology, chromatography, circular dichroism spectroscopy and infrared spectroscopy. A major focus of this renewal proposal will be the extension of our current work on protein aggregation in homogeneous solutions to protein aggregation that occurs due to interactions with interfaces such as those found in delivery devices (e.g., syringes, IV bags, IV lines, and delivery pumps).
Aggregates formed within formulations of therapeutic proteins pose a risk for patient safety by increasing risk for adverse immune responses. By understanding the fundamental mechanisms that lead to therapeutic protein aggregation and associated immune responses, interdiction strategies can be developed that enhance the safety and efficacy of this valuable class of therapeutic molecules.
|Wang, Yiming; Gao, Yuan; Hill, Shannon E et al. (2018) Simulations and Experiments Delineate Amyloid Fibrilization by Peptides Derived from Glaucoma-Associated Myocilin. J Phys Chem B 122:5845-5850|
|Wang, Yiming; Hall, Carol K (2018) Seeding and cross-seeding fibrillation of N-terminal prion protein peptides PrP(120-144). Protein Sci 27:1304-1313|
|Daniels, Austin L; Randolph, Theodore W (2018) Flow Microscopy Imaging Is Sensitive to Characteristics of Subvisible Particles in Peginesatide Formulations Associated With Severe Adverse Reactions. J Pharm Sci 107:1313-1321|
|Calero-Rubio, Cesar; Ghosh, Ranendu; Saluja, Atul et al. (2018) Predicting Protein-Protein Interactions of Concentrated Antibody Solutions Using Dilute Solution Data and Coarse-Grained Molecular Models. J Pharm Sci 107:1269-1281|
|Sallam, Sahar; Dolog, Ivan; Paik, Bradford A et al. (2018) Sequence and Conformational Analysis of Peptide-Polymer Bioconjugates by Multidimensional Mass Spectrometry. Biomacromolecules 19:1498-1507|
|Haider, Michael J; Zhang, Huixi Violet; Sinha, Nairiti et al. (2018) Self-assembly and soluble aggregate behavior of computationally designed coiled-coil peptide bundles. Soft Matter 14:5488-5496|
|Calderon, Christopher P; Daniels, Austin L; Randolph, Theodore W (2018) Deep Convolutional Neural Network Analysis of Flow Imaging Microscopy Data to Classify Subvisible Particles in Protein Formulations. J Pharm Sci 107:999-1008|
|Pardeshi, Neha N; Zhou, Chen; Randolph, Theodore W et al. (2018) Protein Nanoparticles Promote Microparticle Formation in Intravenous Immunoglobulin Solutions During Freeze-Thawing and Agitation Stresses. J Pharm Sci 107:1852-1857|
|Gandhi, Aditya V; Pothecary, Mark R; Bain, David L et al. (2017) Some Lessons Learned From a Comparison Between Sedimentation Velocity Analytical Ultracentrifugation and Size Exclusion Chromatography to Characterize and Quantify Protein Aggregates. J Pharm Sci 106:2178-2186|
|Paik, Bradford A; Mane, Shivshankar R; Jia, Xinqiao et al. (2017) Responsive Hybrid (Poly)peptide-Polymer Conjugates. J Mater Chem B 5:8274-8288|
Showing the most recent 10 out of 101 publications